Familial Pancreatic Cancer PROPHilation Program in Italy
NCT ID: NCT05724992
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
3000 participants
INTERVENTIONAL
2022-12-20
2028-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.
Up to 3,000 participants will be enrolled in this study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Registry of Subjects at Risk of Pancreatic Cancer
NCT04095195
Pancreas Resection for Colorectal Metastasis: Retrospective Study
NCT05714475
Observational Study on GEP-and Pulm-NET Treated at FPG
NCT06402695
Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes
NCT04431076
Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
NCT05754788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saliva testing swab
Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
Saliva swab testing
41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saliva swab testing
41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
* Willingness to participate in saliva-swab-based genetic testing
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General and Pancreatic Surgery Unit, University of Verona
UNKNOWN
Fondazione Valsecchi
UNKNOWN
Associazione Oltre La Ricerca
UNKNOWN
Genomica srl
UNKNOWN
Associazione Italiana per lo Studio del Pancreas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROPH-ITA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.